CHRS · XBRL financial data

Coherus Oncology financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CHRS's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cost of goods and services sold	33	year only	35	28	21	34*	3	3	4	4*	4	4
Research and development	26	26*	28	22	22	21*	24	26	27	31*	22	21
Selling, general and administrative	48	49*	57	35	35	41*	26	26	25	24*	23	21
Operating income (loss)	(32)	(69)*	(43)	(21)	(6)	(42)*	(45)	(45)	(44)	(46)*	(36)	(32)
Interest income	—	year only	—	—	—	year only	—	—	—	year only	—	—
Interest expense	10	11*	11	5	5	5*	2	2	2	2*	2	2
Other income (expense)	2	(0)*	3	1	2	(3)*	0	3	2	2*	1	1
Income tax expense (benefit)	(0)	0*	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(40)	(80)*	103	(13)	(11)	(51)*	(57)	298	(36)	(38)*	(38)	(21)
Earnings per share, basic USD per share	(0.41)	(0.71)*	0.91	(0.11)	(0.09)	(0.44)*	(0.49)	2.57	(0.31)	(0.31)*	(0.28)	(0.13)
Earnings per share, diluted USD per share	(0.41)	(0.71)*	0.83	(0.11)	(0.09)	—	(0.49)	2.57	(0.31)	(0.31)*	(0.28)	(0.13)
Weighted average shares, basic millions of shares	98	112*	113	115	115	115*	116	116	116	120*	136	155
Weighted average shares, diluted millions of shares	98	112*	126	115	115	104*	116	116	116	120*	136	155

Fiscal quarters (CHRS's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	80	103	260	159	98	126	82	217	103	89	115	83
Marketable securities	51	15	—	—	—	—	—	21	88	83	52	22
Inventory	67	63	62	62	48	70	4	5	2	3	5	6
Prepaid and other current assets	16	11	14	14	14	12	16	12	9	6	9	5
Total current assets	444	476	627	558	369	342	310	380	461	207	206	134
Property and equipment, net	6	5	4	3	3	3	2	2	2	1	—	—
Right-of-use asset	—	6	—	—	—	5	—	—	—	3	—	—
Goodwill	1	1	—	—	—	—	—	—	—	—	—	—
Total assets	584	630	764	675	505	449	371	439	517	258	266	191
Accounts payable	37	35	38	77	22	28	41	38	25	10	11	13
Accrued liabilities	67	105	116	61	61	60	46	14	13	20	15	15
Total current liabilities	240	332	538	463	296	283	255	264	372	140	132	76
Lease liability, non-current	—	5	—	—	—	3	—	—	—	1	—	0
Total liabilities	717	823	845	759	593	581	555	320	429	197	187	130
Accumulated deficit	(1,500)	(1,580)	(1,477)	(1,490)	(1,500)	(1,551)	(1,608)	(1,310)	(1,345)	(1,383)	(1,421)	(1,442)
Total stockholders' equity	(134)	(193)	(82)	(84)	(88)	(132)	(183)	120	88	61	79	61
Total liabilities and equity	584	630	764	675	505	449	371	439	517	258	266	191
Common shares outstanding (cover page) millions of shares	111	113	115	115	115	116	116	116	121	150	154	155

Fiscal quarters (CHRS's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(40)	(80)*	103	(13)	(11)	(51)*	(57)	298	(36)	(38)*	(38)	(21)
Stock-based compensation	10*	11*	7	7*	7*	6*	5	5*	3*	3*	2	3*
Depreciation and amortization	1	1*	1	1	0	0*	0	0	0	0*	—	—
Net cash from operating activities	(54)*	(13)*	(47)	60*	(62)*	29*	(26)	(47)*	(46)*	(20)*	(58)	(62)*
Purchases of property and equipment	0*	0*	—	—	—	—	—	—	—	—	—	—
Net cash from investing activities	51*	35*	203	28*	0*	(1)*	(17)	463*	(67)*	(3)*	31	30*
Proceeds from issuing common stock	—	—	—	—	—	year only	—	—	—	—	54	0*
Net cash from financing activities	11*	0*	1	(188)*	(0)*	0*	(0)	(282)*	0*	8*	54	0*
Net change in cash	7*	23*	157	(101)*	(62)*	28*	(44)	134*	(114)*	(14)*	26	(32)*

The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.

Not investment advice. Not affiliated with the U.S. SEC.